Epidemiology of myeloproliferative neoplasms in the United States
Authors:
- Hongwei WangHWHongwei Wang
- Sheikh Usman IqbalSISheikh Usman Iqbal
- Ruben MesaRMRuben Mesa
- 29 July 2013
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 55 (3) , 595-600
Abstract
Myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET) are three classic BCR ABL fusion gene-negative chronic myeloproliferative neoplasms (MPNs). Though rare, it is important to understand the burden of illness of these disorders for public health planning, healthcare insurers and pharmaceutical manufacturers. Therefore, we have described the incidence of MF and prevalence of MF, ET and PV in the United States between 2008 and 2010 based on data from two large health plans. The incidence of primary MF was about 1 per 100 000 per year and did not vary over the study years. The prevalence of PV (44-57 per 100 000) and ET (38-57 per 100 000) was much higher than that of MF (4-6 per 100 000) or subgroups containing MF (post-PV MF = 0.3-0.7 per 100 000; post-ET MF = 0.5-1.1 per 100 000). Additional research using other national databases and/or study designs is needed to substantiate these findings.Keywords
This publication has 19 references indexed in Scilit:
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patientsBlood, 2011
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosisLeukemia Research, 2009
- Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosisBlood, 2008
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelBlood, 2007
- Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)Leukemia Research, 2007
- Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 casesBlood, 2005
- Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemiaThe American Journal of Medicine, 2004
- Trends in the incidence of chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99Journal of Internal Medicine, 2004
- Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995American Journal of Hematology, 1999
- Indirect standardization and multiplicative models for rates, with reference to the age adjustment of cancer incidence and relative frequency dataJournal of Chronic Diseases, 1975